Ibrutinib, as only one agent, is helpful in dealing with CLL, unique subtypes of lymphoma and other B-cell malignancies unless unacceptable toxicity or disease development is observed. As a result of chronic exposure of ibrutinib all through therapy, lymphoma cells could achieve compensatory survival pathways, genetic mutations or clonal collection https://bertolto520fko3.wikievia.com/user